# Research Summary for Acute myeloid leukemia

## Final Refined Summary

# Acute Myeloid Leukemia (AML) Update - May 2025

**Disclaimer:** This report offers a brief overview of recent AML advancements for informational purposes only and should not replace professional medical advice. Always consult your healthcare team for personalized guidance.

## What AML Patients and Caregivers Need to Know Now

This update highlights crucial advancements in AML treatment, offering actionable insights for patients and caregivers. We focus on new therapies, personalized strategies, and proactive management.

### 1. Latest Treatment Options: What's New?

*   **Minimize GVHD After Transplant:** Graft-versus-host disease (GVHD) remains a major concern after stem cell transplants [10]. *Action:* Discuss GVHD prevention with your transplant team. Options include medications like post-transplant cyclophosphamide or tailored immunosuppressant protocols.
*   **Iomab-B: Targeted Radiation for BMT:** Iomab-B (Iodine-131 apamistamab) was **FDA-approved** in December 2023. It delivers targeted radiation to leukemia cells before bone marrow transplant (BMT) in relapsed or refractory AML patients (ages 55-75) who cannot tolerate intensive conditioning. *Important:* Be aware of potential side effects like *severe* low blood counts and mucositis [1].
*   **Targeted Therapies: Precision Strikes Against AML:** These **FDA-approved** therapies target specific genetic mutations in AML cells.
    *   *FLT3* Mutations: Midostaurin (Rydapt) is **FDA-approved** for newly diagnosed AML with chemotherapy. For relapsed/refractory AML, Gilteritinib (Xospata) and Quizartinib (Vanflyta) are **FDA-approved**. *Action:* Monitor for nausea, fatigue, blood count changes, and QTc prolongation (requires ECG monitoring) [2, 3]. Report any new or worsening symptoms to your doctor.
    *   *IDH1/2* Mutations: Options for relapsed/refractory AML include Enasidenib (Idhifa), Olutasidenib (Rezlidhia), and Ivosidenib (Tibsovo), all **FDA-approved**. *Critical:* These drugs can cause differentiation syndrome and QTc prolongation (requires ECG monitoring) [4, 5, 6]. Report any new or worsening symptoms to your doctor immediately.
    *   *KMT2A* Rearrangements or *NPM1* Mutations: Revumenib is showing promise in clinical trials for relapsed/refractory AML [7]. *Note:* This treatment is still experimental and not yet FDA-approved.
    *   *BCL-2* Protein: Venetoclax (Venclexta) is **FDA-approved** and commonly combined with hypomethylating agents or low-dose cytarabine, especially for older or less fit patients. *Monitor closely for tumor lysis syndrome (TLS) and severe low blood counts [8].*
*   **Differentiation Syndrome: Act Fast:** This serious side effect is associated with IDH inhibitors (Enasidenib, Olutasidenib, Ivosidenib) and ATRA (used in APL). *Action:* *Seek immediate medical attention if you experience fever, shortness of breath, weight gain, or bone pain.*

### 2. Key Information for Managing Your AML

*   **Genetic Testing: Understand Your AML:** Identifying specific mutations (*FLT3, IDH1/2, NPM1, TP53, RUNX1*, etc.) and chromosomal abnormalities is crucial. This information helps determine risk, prognosis, and potential response to targeted therapies.
*   **Personalized Treatment Plans: Tailored to You:** Your treatment should be tailored to your specific AML subtype, genetic mutations, age, and overall health. *Action:* Discuss all treatment options with your doctor.
*   **MRD Monitoring: Tracking Treatment Success:** Measurable Residual Disease (MRD) monitoring helps assess treatment effectiveness and guide post-remission strategies.
*   **Act Quickly on These Symptoms:**
    *   **Leukostasis:** This is a medical emergency caused by extremely high leukemia cell counts blocking small blood vessels. *Action:* Seek immediate medical attention for stroke-like symptoms (confusion, headache, shortness of breath) [9].
    *   **Differentiation Syndrome:** As noted above, immediate medical attention is critical.
    *   **Acute Promyelocytic Leukemia (APL):** Rapid diagnosis and treatment are essential. APL has a high risk of severe bleeding/clotting but has high cure rates *if diagnosed and treated quickly* with ATRA and arsenic trioxide.
*   **Standard Chemotherapy and Stem Cell Transplant:** These remain important treatments and should be discussed with your healthcare team.
*   **Clinical Trials: Consider Your Options:** Discuss clinical trial options with your oncologist to access cutting-edge treatments. Find information at ClinicalTrials.gov [11] or the LLS website [12].

### 3. Building Your Support System

*   **Build a Strong Support Network:** Connect with palliative care/supportive care specialists, social workers, nutritionists, and patient navigators.
*   **Prevent Infections:** Due to low blood counts, practice diligent hand hygiene and avoid crowds. Discuss vaccinations with your doctor.
*   **Access These Resources:**
    *   The Leukemia & Lymphoma Society (LLS) [12]: Comprehensive support and research.
    *   CancerCare [13]: Counseling, financial aid, and support groups.
    *   HealthTree Foundation for AML [14]: AML-specific resources and community.
    *   Know AML [15]: Education, awareness, and resources.
    *   Cactus Cancer Society [16] (for young adults): Support for ages 18-45.
    *   Expect Miracles Foundation [17] (financial assistance for young adults): Grants for financial stability after cancer treatment.

**Take Action:** Discuss this information with your healthcare team to make informed decisions about your AML care.

**Bibliography**

[1] Iomab-B (Iodine-131 apamistamab) Approval: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-apamistamab-lu-177-injection-bone-marrow-transplant-conditioning-treatment.
[2] Midostaurin (Rydapt) Prescribing Information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209124lbl.pdf
[3] Gilteritinib (Xospata) Prescribing Information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211240lbl.pdf
[4] Enasidenib (Idhifa) Prescribing Information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/210250lbl.pdf
[5] Olutasidenib (Rezlidhia) Prescribing Information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216053s000lbl.pdf
[6] Ivosidenib (Tibsovo) Prescribing Information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210824lbl.pdf
[7] Revumenib Clinical Trial: https://www.clinicaltrials.gov/study/NCT04065399
[8] Venetoclax (Venclexta) Prescribing Information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209171s005lbl.pdf
[9] Leukostasis: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498199/
[10] Allogeneic Stem cell transplant https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666285/
[11] ClinicalTrials.gov: https://clinicaltrials.gov/
[12] The Leukemia & Lymphoma Society (LLS): https://www.lls.org/
[13] CancerCare: https://www.cancercare.org/
[14] HealthTree Foundation for AML: https://www.healthtree.org/aml
[15] Know AML: https://knowaml.com/
[16] Cactus Cancer Society: https://www.cactuscancer.org/
[17] Expect Miracles Foundation: https://www.expectmiraclesfoundation.org/
